Years of innovative and dedicated research have paid off with the discovery of numerous factors contributing to Alzheimer’s disease (AD) pathology. With a disease as complex as this one, it’s very helpful to find multiple points where it may be possible to slow or halt its progress.

These discoveries have produced a bounty of “druggable targets”.  Unfortunately, only a handful of potential “disease-modifying treatments” ever make it to the point of being tested in clinical trials, where a few are being tested today.

Support is needed for the type of high-risk, high-reward early research where discoveries in basic science may lead to the development of molecules and compounds aimed at reducing toxic protein buildup in AD, improving clearance of toxic particles, and delivering treatments to brain areas. The contributions gained from these exploratory projects at early stages are essential to get the next generation of drugs and therapies to patients.